NewLink Genetics Corporation (NASDAQ:NLNK) was upgraded by analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating in a report issued on Friday, MarketBeat reports. The firm presently has a $26.00 price objective on the biotechnology company’s stock, up from their previous price objective of $7.00. Jefferies Group LLC’s target price would suggest a potential upside of 47.14% from the company’s previous close.

Several other research analysts have also recently issued reports on NLNK. ValuEngine upgraded shares of NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Cantor Fitzgerald set a $32.00 target price on shares of NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Sunday, June 4th. Robert W. Baird restated an “outperform” rating and issued a $25.00 target price on shares of NewLink Genetics Corporation in a report on Monday, June 5th. Finally, Zacks Investment Research upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.

Shares of NewLink Genetics Corporation (NASDAQ NLNK) traded up 29.93% on Friday, hitting $17.67. 31,301,933 shares of the stock were exchanged. The company has a 50 day moving average of $7.51 and a 200 day moving average of $12.84. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The company’s market cap is $519.87 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last issued its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The firm had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. Equities research analysts forecast that NewLink Genetics Corporation will post ($2.82) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/08/newlink-genetics-corporation-nlnk-lifted-to-buy-at-jefferies-group-llc.html.

Hedge funds have recently made changes to their positions in the stock. State of Wisconsin Investment Board purchased a new stake in NewLink Genetics Corporation in the second quarter worth $125,000. Trexquant Investment LP lifted its stake in NewLink Genetics Corporation by 39.1% in the second quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 5,097 shares during the period. Advisor Group Inc. lifted its stake in NewLink Genetics Corporation by 3.4% in the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 600 shares during the period. The Manufacturers Life Insurance Company lifted its stake in NewLink Genetics Corporation by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 556 shares during the period. Finally, First Mercantile Trust Co. purchased a new stake in NewLink Genetics Corporation in the first quarter worth $143,000. 54.78% of the stock is owned by institutional investors.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.